The UK’s pharmaceutical and fine chemical industry is accelerating development of a new generation of manufacturing processes thanks to a new £56 million medicines manufacturing innovation facility.
The state-of-the-art Medicines Manufacturing Innovation Centre (MMIC) will be located in Renfrewshire, Scotland, and led by the Centre for Process Innovation (CPI) in partnership with the University of Strathclyde, the Medicines Manufacturing Industry Partnership (MMIP), and founding industry partners, AstraZeneca and GSK.
The centre will ensure the UK is a technology and innovation leader in small molecule pharmaceutical and fine chemical manufacturing, thereby boosting the competitiveness of both sectors.
Pharmaceutical companies are investing millions to speed up manufacturing processes, reducing waste and cost, and future medicines will also require innovative manufacturing technologies.
With a collaborative innovation culture and state-of the art facilities, the new Medicines Manufacturing Innovation Centre will develop highly efficient and effective technologies.
As a flexible and adaptable building, the centre will enable industry, academia, healthcare providers and regulators to work collaboratively to address challenges along the medicines supply chain.
The UK medicines manufacturing community will be assisted through in-house industrial and academic experts, thought leadership and a support structure to help small and medium sized enterprises and start-ups innovate and grow.
Enhancing the link between those doing research and development and those manufacturing drugs will reduce the risk in the process of adopting disruptive technologies and accelerate the translation of the UK’s strong research base into new industrial approaches of the future. Read more